论文部分内容阅读
目的研究小剂量普伐他汀与非诺贝特联合治疗混合型高血脂症临床疗效及安全性。方法将我院2015年1月~2016年1月收诊的72例混合型高血脂症患者作为研究对象,并随机分为对照组和观察组,每组各36例。研究组采用普伐他汀和非诺贝特联合治疗,规定非诺贝特使用量200 mg,普伐他汀使用量10 mg,且医嘱研究对象每天晚餐服用1次;对照组仅服用普伐他汀药物,医嘱患者每天服用普伐他汀1次,服用量20 mg,两组均治疗3个月。观察对比两组患者总胆固醇、甘油三酯、低密度脂蛋白以及不良反应率。结果对照组患者低密度脂蛋白为(4.10±0.24)mmol/L、甘油三酯为(2.99±0.68)mmol/L、总胆固醇指标为(6.32±1.22)mmol/L,研究组患者低密度脂蛋白为(3.09±0.33)mmol/L、甘油三酯为(1.59±0.08)mmol/L、总胆固醇为(4.99±0.44)mmol/L,研究组患者的各指标均优于对照组,两组各指标对比,差异具有统计学意义(P<0.05)。对照组不良反应发生率为61.11%,研究组不良反应发生率为22.22%,研究组患者不良反应发生率低于对照组,差异具有统计学意义(P<0.05)。结论小剂量普伐他汀与非诺贝特联合治疗混合型高血脂症,可有效降低患者的低密度脂蛋白、总胆固醇和甘油三酯,降低患者用药不良反应,治疗安全性更高。
Objective To study the clinical efficacy and safety of low-dose pravastatin combined with fenofibrate in the treatment of mixed hyperlipidemia. Methods A total of 72 patients with hyperlipidemia admitted to our hospital from January 2015 to January 2016 were randomly divided into control group and observation group, with 36 cases in each group. The study group using pravastatin and fenofibrate combination therapy, the provisions of fenofibrate 200 mg, pravastatin 10 mg, and the doctor ordered the subjects to take dinner once a day; the control group taking only pravastatin drugs , Patients prescribed pravastatin 1 times daily, taking 20 mg, both groups were treated for 3 months. The levels of total cholesterol, triglyceride, low density lipoprotein, and adverse reactions were compared between the two groups. Results In the control group, LDL was (4.10 ± 0.24) mmol / L, triglyceride was (2.99 ± 0.68) mmol / L and total cholesterol was (6.32 ± 1.22) mmol / L in the study group. (3.09 ± 0.33) mmol / L, (1.59 ± 0.08) mmol / L and (4.99 ± 0.44) mmol / L of total cholesterol in the study group were higher than those in the control group The indicators of contrast, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the control group was 61.11%, the incidence of adverse reactions in the study group was 22.22%, and the incidence of adverse reactions in the study group was lower than that in the control group (P <0.05). Conclusions Low-dose pravastatin combined with fenofibrate in combination with hyperlipidemia can effectively reduce LDL, total cholesterol and triglyceride in patients and reduce adverse drug reactions in patients with higher safety of treatment.